{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T22:00:29Z","timestamp":1764194429905},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The peritoneum is the second most common site for metastasis in patients with colorectal cancer. Various factors have been studied to identify patients at risk of developing peritoneal carcinomatosis (PC), including T4 tumors. The objectives were to assess the incidence of synchronous and metachronous PC, explore potential risk factors for developing PC as the only site of metastasis, and identify which patients might be candidates for prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We conducted a retrospective analysis of 125 patients with pT4 colon cancer who underwent surgery in a single center between January 2010 and December 2014.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Of the 947 colon cancer patients who underwent surgery, 125 (13.2%) were diagnosed with pT4a or b colon carcinoma. The median follow-up was 3.7\u00a0years. The overall rate of PC was 34.3%, being synchronous in 12% and metachronous in 22.3% of cases. The 8% and 6% of synchronous and metachronous cases of PC respectively were isolated (single site) metastasis. The incidence of PC was 6.1% at 1\u00a0year and 14.5% at 3\u00a0years after surgery. pT4 was not found to be an independent risk factor for the development of PC (<jats:italic>p<\/jats:italic>\u2009=\u20090.231). Nonetheless, the rate of metachronous PC as a single site of metastasis was higher in patients with pT4 tumors and peritoneal nodules around the primary tumor and\/or tumor perforation (<jats:italic>p<\/jats:italic>\u2009=\u20090.027) and\/or who underwent emergency surgery (<jats:italic>p<\/jats:italic>\u2009=\u20090.043) than other patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Considering pT4 tumor stage as the only risk factor for the development of PC in deciding whether to administer prophylactic HIPEC would lead to unjustified overtreatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.1245\/s10434-019-07970-z","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T20:27:04Z","timestamp":1572467224000},"page":"1094-1100","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prophylactic HIPEC in pT4 Colon Tumors: Proactive Approach or Overtreatment?"],"prefix":"10.1245","volume":"27","author":[{"given":"Nerea Borda","family":"Arrizabalaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda Enriquez","family":"Navascu\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garazi Elorza","family":"Echaniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda Saralegui","family":"Ansorena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Placer","family":"Gal\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xabier Arteaga","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyre Velaz","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,29]]},"reference":[{"issue":"5","key":"7970_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359\u201386.","journal-title":"Int J Cancer"},{"key":"7970_CR2","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/BF02050360","volume":"34","author":"JT Brodsky","year":"1991","unstructured":"Brodsky JT, Cohen AM. Peritoneal seeding following potentially curative resection of colonic carcinoma: implications for adjuvant therapy. Dis Colon Rectum. 1991;34:723\u20137.","journal-title":"Dis Colon Rectum."},{"key":"7970_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00384-014-2085-6","volume":"30","author":"MAG Elferink","year":"2015","unstructured":"Elferink MAG, de Jong KP, Klaase JM, et al. Metachronous metastases from colorectal cancer: a population-based study in North-East Netherlands. Int J Colorectal Dis. 2015;30:205\u201312.","journal-title":"Int J Colorectal Dis"},{"issue":"12","key":"7970_CR4","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1046\/j.1365-2168.2002.02274.x","volume":"89","author":"DG Jayne","year":"2002","unstructured":"Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89(12):1545\u201350.","journal-title":"Br J Surg"},{"issue":"3","key":"7970_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S1055-3207(03)00044-9","volume":"12","author":"O Glehen","year":"2003","unstructured":"Glehen O, Osinsky D, Beaujard AC, et al. Natural history of peritoneal carcinomatosis from nongynecologic malignancies. Surg Oncol Clin N Am. 2003;12(3):729\u201339.","journal-title":"Surg Oncol Clin N Am"},{"issue":"4 Suppl 6","key":"7970_CR6","first-page":"83","volume":"16","author":"PH Sugarbaker","year":"1989","unstructured":"Sugarbaker PH, Cunliffe WJ, Belliveau J, et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol. 1989;16(4 Suppl 6):83\u201397.","journal-title":"Semin Oncol"},{"issue":"1","key":"7970_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.1988.6.1.106","volume":"6","author":"BD Minsky","year":"1988","unstructured":"Minsky BD, Mies C, Rich TA, et al. Potentially curative surgery of colon cancer: patterns of failure and survival. J Clin Oncol. 1988;6(1):106\u201318.","journal-title":"J Clin Oncol"},{"issue":"16","key":"7970_CR8","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","volume":"22","author":"O Glehen","year":"2004","unstructured":"Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284\u201392.","journal-title":"J Clin Oncol"},{"issue":"4","key":"7970_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/jso.21053","volume":"98","author":"J Esquivel","year":"2008","unstructured":"Esquivel J, Elias D, Baratti D, et al. Consensus statement on the locoregional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol. 2008;98(4):263\u20137.","journal-title":"J Surg Oncol"},{"issue":"3","key":"7970_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3748\/wjg.v23.i3.377","volume":"23","author":"D Cortes-Guiral","year":"2017","unstructured":"Cortes-Guiral D, Elias D, Cascales-Campos PA, et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy for patients with colorectal cancer at high risk of peritoneal carcinomatosis: does it really save lives? World J Gastroenterol. 2017;23(3):377\u201381.","journal-title":"World J Gastroenterol"},{"issue":"29","key":"7970_CR11","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1200\/JCO.2007.11.0833","volume":"25","author":"JS Tomlinson","year":"2007","unstructured":"Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575\u201380.","journal-title":"J Clin Oncol"},{"key":"7970_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","volume":"27","author":"D Elias","year":"2009","unstructured":"Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681\u20135.","journal-title":"J Clin Oncol"},{"key":"7970_CR13","doi-asserted-by":"publisher","first-page":"5608","DOI":"10.1002\/cncr.25356","volume":"116","author":"O Glehen","year":"2010","unstructured":"Glehen O, Gilly FN, Boutitie F, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1290 patients. Cancer. 2010;116:5608\u201318.","journal-title":"Cancer"},{"key":"7970_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/SLA.0b013e318255486a","volume":"256","author":"G Passot","year":"2012","unstructured":"Passot G, Vaudoyer D, Cotte E, et al. Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis. Ann Surg. 2012;256:125\u20139.","journal-title":"Ann Surg"},{"key":"7970_CR15","first-page":"907","volume":"13","author":"M Gelli","year":"2017","unstructured":"Gelli M, Huguenin J, Cerebelli C, et al. Strategies to prevent peritoneal carcinomatosis arising from colorectal cancer. Future Med. 2017;13:907\u201318.","journal-title":"Future Med"},{"issue":"2","key":"7970_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ciresp.2017.11.006","volume":"96","author":"\u00c1 Serrano Del Moral","year":"2018","unstructured":"Serrano Del Moral \u00c1, P\u00e9rez Viejo E, Manzanedo Romero I, et al. Cirug\u00eda de second look m\u00e1s HIPEC en pacientes sin evidencia de recidiva con alto riesgo de desarrollar carcinomatosis tras resecci\u00f3n de c\u00e1ncer colorrectal. Cir Esp. 2018;96(2):97\u2013102.","journal-title":"Cir Esp"},{"issue":"1","key":"7970_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1245\/s10434-016-5488-5","volume":"24","author":"D Baratti","year":"2017","unstructured":"Baratti D, Kusamura S, Iusco D, et al. Hyperthermic intraperitoneal Chemotherapy (HIPEC) at the time of primary curative surgery in patients with colorectal cancer at high risk for metachronous peritoneal metastases. Ann Surg Oncol. 2017;24(1):167\u201375.","journal-title":"Ann Surg Oncol"},{"key":"7970_CR18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/SLA.0b013e31822638f6","volume":"254","author":"D Elias","year":"2011","unstructured":"Elias D, Honor\u00e9 C, Dumont F, et al. Results of systematic second look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2011;254:289\u201393.","journal-title":"Ann Surg"},{"key":"7970_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1245\/s10434-012-2473-5","volume":"20","author":"C Honor\u00e9","year":"2013","unstructured":"Honor\u00e9 C, Go\u00e9r\u00e9 D, Souadka A, et al. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol. 2013;20:183\u201392.","journal-title":"Ann Surg Oncol"},{"key":"7970_CR20","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12885-015-1430-7","volume":"15","author":"CE Klaver","year":"2015","unstructured":"Klaver CE, et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer. 2015;15:428\u201337.","journal-title":"BMC Cancer"},{"key":"7970_CR21","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1093\/annonc\/mds173","volume":"23","author":"D Hompes","year":"2012","unstructured":"Hompes D, Tiek J, Wolthuis A. HIPEC in T4a colon cancer: a defendable treatment to improve the oncologic outcome? Ann Oncol. 2012;23:3123\u20139.","journal-title":"Ann Oncol"},{"key":"7970_CR22","first-page":"425","volume":"134","author":"G Folprecht","year":"2007","unstructured":"Folprecht G, K\u00f6hne C, Lutz M, et al. Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Cancer Treat Res. 2007;134:425\u201340.","journal-title":"Cancer Treat Res"},{"issue":"5","key":"7970_CR23","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1245\/s10434-013-3461-0","volume":"21","author":"HC Van Santvoort","year":"2014","unstructured":"Van Santvoort HC, Braam HJ, Spekreijse KR, et al. Peritoneal carcinomatosis in t4 colorectal cancer: occurrence and risk factors. Ann Surg Oncol. 2014;21(5):1686\u201391.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"7970_CR24","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/bjs.8679","volume":"99","author":"J Segelman","year":"2012","unstructured":"Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99(5):699\u2013705.","journal-title":"Br J Surg"},{"key":"7970_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1745-6215-11-62","volume":"11","author":"RT Ripley","year":"2010","unstructured":"Ripley RT, Davis JL, Kemp CD, et al. Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases. Trials. 2010;11:62.","journal-title":"Trials"},{"issue":"15","key":"7970_CR26","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1200\/JCO.2018.36.15_suppl.3531","volume":"36","author":"D Goere","year":"2018","unstructured":"Goere D, Glehen O, Quenet F, et al. Results of a randomized phase 3 study evaluating the potential benefit of a second look surgery plus HIPEC in patients at high risk of developing colorrectal peritoneal disease. J Clin Oncol. 2018;36(15):3531.","journal-title":"J Clin Oncol"},{"key":"7970_CR27","unstructured":"Quenet F, Elias D, Roca L, et al. A UNICANCER phase III trial of Hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorrectal peritoneal carcinomatosis (PC): PRODIGE 7 (NCT 00769405)."},{"key":"7970_CR28","first-page":"183","volume":"18","author":"A Arjona","year":"2018","unstructured":"Arjona A, Barrios P, Boldo-Roda E, et al. HIPECT4: Multicentre randomized clinical trial to evaluate safety and efficacy of HIPEC with Mitomycin C used during surgery for the treatment of locally advanced colorectal carcinoma. BMC. 2018;18:183.","journal-title":"BMC"},{"key":"7970_CR29","unstructured":"Proactive management of endoperitoneal spread in colonic cancer. PROMENADE trial (NCT 02974556)."},{"key":"7970_CR30","unstructured":"Trial evaluating surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) in treating patients with a high risk of developing colorectal peritoneal carcinomatosis (NCT 02179489)."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07970-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-07970-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07970-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:30:36Z","timestamp":1603845036000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-07970-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,29]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["7970"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-07970-z","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,29]]},"assertion":[{"value":"1 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no commercial interests to declare and did not receive any external financial or material support.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}